Gastrointestinal endoscopy · 2015
Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer.
Сравнительное исследованиеКонтролируемое клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Jae Hyuk, Kim Eun Soo, Lee Yoo Jin, Cho Kwang Bum, Park Kyung Sik, Jang Byoung Kuk, Chung Woo Jin, Hwang Jae Seok, Ryu Seung Wan
Аннотация
BACKGROUND: The quality of life (QOL) of patients who survive early gastric cancer (EGC) is an area of increasing interest.
OBJECTIVE: To compare the QOL and degree of worry of cancer recurrence in EGC patients who underwent endoscopic submucosal dissection (ESD) or surgery.
DESIGN: Cross-sectional study.
SETTINGS: A tertiary referral center.
PATIENTS: A total of 565 patients with EGC who received ESD or surgery.
INTERVENTION: Questionnaires.
MAIN OUTCOME MEASUREMENTS: QOL was evaluated using the Short-form Health Survey and the European Organization for Research and Treatment of Cancer QOL questionnaires (QLQ-C30 and EORTC-QLQ-STO22). Mood disorders and the worry of cancer recurrence were estimated using the Hospital Anxiety and Depression Scale (HADS) and Worry of Cancer Scale, respectively.
RESULTS: Questionnaires were completed by 55.7% of the ESD (137/246) and 58.9% of the surgery (188/319) patients. The surgery group had more QOL-related symptomatic and functional problems, including fatigue (P=.044), nausea/vomiting (P=.032), appetite loss (P=.023), diarrhea (P<.001), pain (P=.013), reflux symptoms (P=.005), eating restrictions (P<.001), anxiety (P=.015), taste impairment (P=.011), and poor body image (P<.001). The ESD group had significantly higher worry of cancer recurrence scores after adjusting for covariates, especially when visiting their physicians. The HADS results did not differ between the groups.
LIMITATIONS: Cross-sectional design.
CONCLUSIONS: Endoscopic treatment for EGC provides a better QOL, but stomach preservation might provoke cancer recurrence worries. Endoscopists should address this issue for relieving a patient's concern of cancer recurrence during follow-up period after ESD. (
CLINICAL TRIAL REGISTRATION NUMBER: WHO ICTRP KCT0000791.).
OBJECTIVE: To compare the QOL and degree of worry of cancer recurrence in EGC patients who underwent endoscopic submucosal dissection (ESD) or surgery.
DESIGN: Cross-sectional study.
SETTINGS: A tertiary referral center.
PATIENTS: A total of 565 patients with EGC who received ESD or surgery.
INTERVENTION: Questionnaires.
MAIN OUTCOME MEASUREMENTS: QOL was evaluated using the Short-form Health Survey and the European Organization for Research and Treatment of Cancer QOL questionnaires (QLQ-C30 and EORTC-QLQ-STO22). Mood disorders and the worry of cancer recurrence were estimated using the Hospital Anxiety and Depression Scale (HADS) and Worry of Cancer Scale, respectively.
RESULTS: Questionnaires were completed by 55.7% of the ESD (137/246) and 58.9% of the surgery (188/319) patients. The surgery group had more QOL-related symptomatic and functional problems, including fatigue (P=.044), nausea/vomiting (P=.032), appetite loss (P=.023), diarrhea (P<.001), pain (P=.013), reflux symptoms (P=.005), eating restrictions (P<.001), anxiety (P=.015), taste impairment (P=.011), and poor body image (P<.001). The ESD group had significantly higher worry of cancer recurrence scores after adjusting for covariates, especially when visiting their physicians. The HADS results did not differ between the groups.
LIMITATIONS: Cross-sectional design.
CONCLUSIONS: Endoscopic treatment for EGC provides a better QOL, but stomach preservation might provoke cancer recurrence worries. Endoscopists should address this issue for relieving a patient's concern of cancer recurrence during follow-up period after ESD. (
CLINICAL TRIAL REGISTRATION NUMBER: WHO ICTRP KCT0000791.).
Предметные рубрики MeSH
AgedAnxietyAppetiteBody ImageCross-Sectional StudiesDepressionDiarrheaDissectionFatigueFemaleGastric MucosaGastroesophageal RefluxGastroscopyHumansMaleMiddle AgedNauseaNeoplasm Recurrence, LocalPainPsychiatric Status Rating ScalesQuality of LifeStomach NeoplasmsSurveys and QuestionnairesTaste DisordersVomiting